SS Innovations International, Inc. (NASDAQ: SSII) announced a significant expansion in the utilization and global reach of its SSi Mantra surgical robotic system, according to a recent investor update. As of September 8, 2026, the company reported 14,103 cumulative procedures performed using the SSi Mantra, representing a 79% increase from 7,885 procedures at the end of 2025. The installed base of systems grew 42% to 238 units, up from 168 at year-end 2025. These figures underscore the accelerating adoption of the company's robotic surgery platform across multiple markets.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the system, which has been used for more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. Additionally, the company highlighted 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31, including a more than 13,600-mile telesurgery between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India.
These developments matter because they demonstrate SS Innovations' ability to penetrate both established and emerging markets with a cost-effective alternative to traditional robotic surgery systems. The company's focus on affordability and accessibility could disrupt the global surgical robotics market, which has historically been dominated by high-cost players. The expansion into cardiac surgery, pediatrics, and telesurgery further showcases the versatility and clinical potential of the SSi Mantra platform.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. The company also believes it can obtain European Union CE marking certification by year-end 2026. These regulatory milestones, if achieved, would open up two of the largest and most lucrative healthcare markets in the world, potentially driving further procedure growth and system installations.
For investors, the update signals strong momentum in both clinical adoption and geographic expansion. The 79% procedure growth and 42% installed base growth reflect increasing trust among surgeons and hospitals. With regulatory clearances on the horizon, SS Innovations is positioning itself to compete more directly with established robotic surgery giants. The company's progress in telesurgery also highlights its technological capabilities, which could enable remote surgical care in underserved regions.
To view the full report, visit https://ibn.fm/DJILj. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. For more information about InvestorWire, please visit https://www.InvestorWire.com.
